View in EDS

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.

Saved in:
Bibliographic Details
Title: HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
Authors: Villacampa G; Statistics Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; SOLTI Cancer Research Group, Barcelona, Spain; Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain., Pascual T; SOLTI Cancer Research Group, Barcelona, Spain; Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain., Tarantino P; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Cortés J; Medica Scientia Innovation Research, Barcelona, Spain; International Breast Cancer Center, Pangaea Oncology, Quiron Group, Barcelona, Spain; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain., Perez-García J; Medica Scientia Innovation Research, Barcelona, Spain; International Breast Cancer Center, Pangaea Oncology, Quiron Group, Barcelona, Spain., Llombart-Cussac A; Medica Scientia Innovation Research, Barcelona, Spain; Arnau de Vilanova Hospital, Valencia, Spain., Conte P; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy., Mancino M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Guarneri V; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy., Dieci MV; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy., Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Schettini F; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain., Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Reveal Genomics, Barcelona, Spain., Griguolo G; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy., de Castro BA; Department of Medical Oncology, INIBIC, A Coruña University Hospital, A Coruña, Spain., Reboredo C; Department of Medical Oncology, INIBIC, A Coruña University Hospital, A Coruña, Spain., Antolín S; Department of Medical Oncology, INIBIC, A Coruña University Hospital, A Coruña, Spain., Bueno-Muiño C; Hospital Infanta Cristina-Parla, Madrid, Spain., Echavarría I; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain., López-Tarruella S; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain., Massarrah T; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain., Del Monte-Millán M; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain., Martín M; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain., Buckingham W; Reveal Genomics, Barcelona, Spain., Parker JS; Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Vivancos A; Cancer Genomics Group, VHIO, Barcelona, Spain., Polyak K; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Filho OM; Department of Pathology, Center for Advanced Medical Diagnostics, Brigham and Women's Hospital, Boston, MA, USA., Wolff AC; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., DeMichele A; Department of Oncology, University of Pennsylvania, Philadelphia, PA, USA., Tung NM; Beth Israel Deaconess Medical Center, Boston, MA, USA., Perou CM; Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Paré L; Reveal Genomics, Barcelona, Spain., Villagrasa P; Reveal Genomics, Barcelona, Spain., Prat A; Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain; Institute of Oncology-Quirón, Barcelona, Spain. Electronic address: alprat@clinic.cat., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Source: The Lancet. Oncology [Lancet Oncol] 2025 Aug; Vol. 26 (8), pp. 1100-1112. Date of Electronic Publication: 2025 Jul 14.
Publication Type: Journal Article; Meta-Analysis; Systematic Review
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40675165
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Villacampa+G%22">Villacampa G</searchLink>; Statistics Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; SOLTI Cancer Research Group, Barcelona, Spain; Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Pascual+T%22">Pascual T</searchLink>; SOLTI Cancer Research Group, Barcelona, Spain; Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Tarantino+P%22">Tarantino P</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Cortés+J%22">Cortés J</searchLink>; Medica Scientia Innovation Research, Barcelona, Spain; International Breast Cancer Center, Pangaea Oncology, Quiron Group, Barcelona, Spain; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Perez-García+J%22">Perez-García J</searchLink>; Medica Scientia Innovation Research, Barcelona, Spain; International Breast Cancer Center, Pangaea Oncology, Quiron Group, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Llombart-Cussac+A%22">Llombart-Cussac A</searchLink>; Medica Scientia Innovation Research, Barcelona, Spain; Arnau de Vilanova Hospital, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Conte+P%22">Conte P</searchLink>; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.<br /><searchLink fieldCode="AU" term="%22Mancino+M%22">Mancino M</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Guarneri+V%22">Guarneri V</searchLink>; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.<br /><searchLink fieldCode="AU" term="%22Dieci+MV%22">Dieci MV</searchLink>; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.<br /><searchLink fieldCode="AU" term="%22Waks+AG%22">Waks AG</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Schettini+F%22">Schettini F</searchLink>; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Brasó-Maristany+F%22">Brasó-Maristany F</searchLink>; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Reveal Genomics, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Griguolo+G%22">Griguolo G</searchLink>; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.<br /><searchLink fieldCode="AU" term="%22de+Castro+BA%22">de Castro BA</searchLink>; Department of Medical Oncology, INIBIC, A Coruña University Hospital, A Coruña, Spain.<br /><searchLink fieldCode="AU" term="%22Reboredo+C%22">Reboredo C</searchLink>; Department of Medical Oncology, INIBIC, A Coruña University Hospital, A Coruña, Spain.<br /><searchLink fieldCode="AU" term="%22Antolín+S%22">Antolín S</searchLink>; Department of Medical Oncology, INIBIC, A Coruña University Hospital, A Coruña, Spain.<br /><searchLink fieldCode="AU" term="%22Bueno-Muiño+C%22">Bueno-Muiño C</searchLink>; Hospital Infanta Cristina-Parla, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Echavarría+I%22">Echavarría I</searchLink>; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22López-Tarruella+S%22">López-Tarruella S</searchLink>; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Massarrah+T%22">Massarrah T</searchLink>; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Del+Monte-Millán+M%22">Del Monte-Millán M</searchLink>; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Martín+M%22">Martín M</searchLink>; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Buckingham+W%22">Buckingham W</searchLink>; Reveal Genomics, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Parker+JS%22">Parker JS</searchLink>; Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Vivancos+A%22">Vivancos A</searchLink>; Cancer Genomics Group, VHIO, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Polyak+K%22">Polyak K</searchLink>; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Filho+OM%22">Filho OM</searchLink>; Department of Pathology, Center for Advanced Medical Diagnostics, Brigham and Women's Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wolff+AC%22">Wolff AC</searchLink>; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22DeMichele+A%22">DeMichele A</searchLink>; Department of Oncology, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Tung+NM%22">Tung NM</searchLink>; Beth Israel Deaconess Medical Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Perou+CM%22">Perou CM</searchLink>; Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Paré+L%22">Paré L</searchLink>; Reveal Genomics, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Villagrasa+P%22">Villagrasa P</searchLink>; Reveal Genomics, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Prat+A%22">Prat A</searchLink>; Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain; Institute of Oncology-Quirón, Barcelona, Spain. Electronic address: alprat@clinic.cat.<br /><searchLink fieldCode="AU" term="%22Tolaney+SM%22">Tolaney SM</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2025 Aug; Vol. 26 (8), pp. 1100-1112. <i>Date of Electronic Publication: </i>2025 Jul 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Meta-Analysis; Systematic Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40675165
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(25)00276-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1100
    Titles:
      – TitleFull: HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Villacampa G
      – PersonEntity:
          Name:
            NameFull: Pascual T
      – PersonEntity:
          Name:
            NameFull: Tarantino P
      – PersonEntity:
          Name:
            NameFull: Cortés J
      – PersonEntity:
          Name:
            NameFull: Perez-García J
      – PersonEntity:
          Name:
            NameFull: Llombart-Cussac A
      – PersonEntity:
          Name:
            NameFull: Conte P
      – PersonEntity:
          Name:
            NameFull: Mancino M
      – PersonEntity:
          Name:
            NameFull: Guarneri V
      – PersonEntity:
          Name:
            NameFull: Dieci MV
      – PersonEntity:
          Name:
            NameFull: Waks AG
      – PersonEntity:
          Name:
            NameFull: Schettini F
      – PersonEntity:
          Name:
            NameFull: Brasó-Maristany F
      – PersonEntity:
          Name:
            NameFull: Griguolo G
      – PersonEntity:
          Name:
            NameFull: de Castro BA
      – PersonEntity:
          Name:
            NameFull: Reboredo C
      – PersonEntity:
          Name:
            NameFull: Antolín S
      – PersonEntity:
          Name:
            NameFull: Bueno-Muiño C
      – PersonEntity:
          Name:
            NameFull: Echavarría I
      – PersonEntity:
          Name:
            NameFull: López-Tarruella S
      – PersonEntity:
          Name:
            NameFull: Massarrah T
      – PersonEntity:
          Name:
            NameFull: Del Monte-Millán M
      – PersonEntity:
          Name:
            NameFull: Martín M
      – PersonEntity:
          Name:
            NameFull: Buckingham W
      – PersonEntity:
          Name:
            NameFull: Parker JS
      – PersonEntity:
          Name:
            NameFull: Vivancos A
      – PersonEntity:
          Name:
            NameFull: Polyak K
      – PersonEntity:
          Name:
            NameFull: Filho OM
      – PersonEntity:
          Name:
            NameFull: Wolff AC
      – PersonEntity:
          Name:
            NameFull: DeMichele A
      – PersonEntity:
          Name:
            NameFull: Tung NM
      – PersonEntity:
          Name:
            NameFull: Perou CM
      – PersonEntity:
          Name:
            NameFull: Paré L
      – PersonEntity:
          Name:
            NameFull: Villagrasa P
      – PersonEntity:
          Name:
            NameFull: Prat A
      – PersonEntity:
          Name:
            NameFull: Tolaney SM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2025 Aug
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1